Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Risk Management
3 Ways Finance Is Armoring Up for a Future of Disruption
Finance leaders are breaking down silos, improving planning methodologies, and upgrading tech tools to safeguard their businesses.
By
Alessio Lolli
| August 15, 2022
Read More
Resources
CFO Live
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
Sign Up
Sponsored by
Pfizer
Tax
Did Treasury Target Pfizer-Allergan Inversion?
The Obama Administration and the Allergan CEO disagree about whether the government wanted specifically to kill the giant drug merger.
By
David Katz and Katie Kuehner-Hebert
| April 6, 2016
Read More
Tax
Socially Responsible Companies Pay Lower Taxes
A new study debunks the common notion that companies with high CSR ratings do not practice aggressive tax avoidance.
By
David McCann
| December 16, 2015
Read More
Tax
Clinton to Propose Crackdown on Inversions
The presidential candidate would impose an "exit tax" on tax inversion deals that let U.S. firms reduce their taxes by merging with companies overseas.
By
Matthew Heller
| December 7, 2015
Read More
Corporate Finance
Finance Roundup for Executives
Be informed, get involved, and shape the world through finance. Here's today's CFO roundup.
By
Kerry Maruna
| November 24, 2015
Read More
Tax
Pfizer Buys Allergan for $160B
The companies predict the combined entity would have more than $25 billion in operating cash flow starting in 2018.
By
Katie Kuehner-Hebert
| November 23, 2015
Read More
Management Accounting
Strong Dollar Deflates Earnings
Blue chips, including P&G, Dupont, and Pfizer, feel the effects of "unprecedented currency devaluations."
By
Katie Kuehner-Hebert
| January 27, 2015
Read More
Risk
Mergers and Acquisitions: Coming Unstuck
When giant deals fail, life rarely goes back to normal.
By
Economist Staff
| August 11, 2014
Read More
Risk
Treasury Proposal Would Thwart Corporate Inversions
In March the Treasury Department proposed an amendment to tax law, taking effect in 2015, that would prevent most corporate inversion transactions.
By
Vincent Ryan
| May 8, 2014
Read More
People
Divestitures Can Spawn Costly Human-Capital Errors
Amid a rush of spinoffs and carve-outs, parties to deals must watch out for people-related things they assume will work but won’t and important but often-overlooked considerations.
By
David McCann
| July 12, 2013
Read More
The Economy
Financing Medical Research: Disease or Cure?
How securitisation may help your health.
By
Economist Staff
| January 25, 2013
Read More
M&A
The Prescription for Pharma Is Revenue Growth
Despite the hullabaloo about health-care reform, investors still reward revenue growth by pharmaceutical companies. But that growth requires organic and acquisitive reinvestment.
By
Gregory V. Milano and John R. Cryan
| April 4, 2012
Read More
Growth Strategies
Pfizer Defiant
How David Shedlarz challenges the analysts.
By
Stephen Barr
| July 1, 1999
Read More
Previous